Spurred By Necessity, Industry And Academia Are Learning To Share
Executive Summary
After a prior era of failed collaborations, industry and academia are increasingly joining forces in ways that better accommodate each others’ capabilities and goals – and, they hope, will create more value and ultimately greater improvements to human health.
You may also be interested in...
Check Again: The Problem With Reproducibility
Promising academic results prove elusive when the experiments are run again, threatening reputations and wasting industry resources. Everyone is scrambling for a fix, but is the problem as bad as it seems, and do we really need a top-down solution?
Pfizer, Alliance For Lupus Research To Co-Fund Translational Projects
Pfizer’s partnership with the Alliance for Lupus Research to co-fund translational projects within the context of the pharma’s CTI program is a first. It’s a novel way to speed promising science into the clinic. But can Pfizer, a non-profit research foundation, and academic researchers reconcile their new roles and variant cultures to make the model work?
Could "Calculated Risks" In China Help Solve Global R&D Challenges? Bayer Thinks So
SHANGHAI - China could serve as the catalyst for a new model of dealmaking that emphasizes more flexible and strategic partnerships to drive R&D productivity, but only if Big Pharma is willing to take "calculated risks," according to Bayer Healthcare AG Chairman Jorg Reinhardt